Pacira Pharmaceuticals (NASDAQ:PCRX) had its stock rating reiterated as ‘Outperform’ in a report released by analysts at Wedbush.
Wedbush today set a target price of 93 on the company’s stock. According to the analyst this now indicates there is a potential increase of 180.12% from Pacira Pharmaceuticals’s current price of 33.2.
Over the last twelve months Pacira Pharmaceuticals’s stock price has decreased by -19.28% from 41.13 to 33.2.
There are currently 37,278,000 shares in issue with a current share value of 33.2 giving Pacira Pharmaceuticals a market capitalisation of 1.24B USD .
Pacira Pharmaceuticals (NASDAQ:PCRX) has a 50 day moving average of 37.4 and a 200 day moving average of 43.27. The 52 week high for the share price is 80.25 while the 52 week low for the stock is 31.08.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).